All In Biotech

Drug Trial Radar · NCT05461768

A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M07D1 for Injection in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

Aug 9, 2022

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Sponsor type
Industry
Collaborators
SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
First posted
Jul 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In phase Ia study, the safety and tolerability of BL-B07D1 in patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-M07D1. In phase Ib study, the safety and tolerability of BL-M07D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-M07D1 in patients

Conditions

  • Breast Cancer
  • Locally Advanced or Metastatic Solid Tumor

Interventions

  • BL-M07D1Drug

    Administration by intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ia: Dose limiting toxicity (DLT)Time frame: Up to 21 days after the first dose
  2. Phase Ia: Maximum tolerated dose (MTD)Time frame: Up to 21 days after the first dose
  3. Phase Ib: Phase II clinical study recommended dose (RP2D)Time frame: Up to 21 days after the first dose

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • Dongguan People's Hospital

    Dongguan, Guangdong, China · Recruiting

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    Guangdong, Guangzhou, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

  • Jinan Central Hospital

    Jinan, Shandong, China · Recruiting

  • Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.